Asker Healthcare Group (OM:ASKER) Stock Faces Rich Valuation As EPS Growth Reinforces Bullish Narratives

Asker Healthcare Group (OM:ASKER) has put solid numbers on the table for Q2 2026, with revenue of SEK4.7b and basic EPS of SEK0.57 alongside net income of SEK219m. On a trailing twelve month basis, EPS stands at SEK1.92 on revenue of SEK18.0b and net income of SEK684m. The company has seen quarterly revenue move from SEK4.0b in Q2 2025 to SEK4.7b in Q2 2026, with basic EPS shifting from SEK0.34 to SEK0.57 over the same period. Trailing net profit margin sits at 3.8% versus 2.7% a year earlier, setting the scene for a results season where profitability is increasingly in focus for investors.

See our full analysis for Asker Healthcare Group.

With the latest figures in place, the next step is to see how these results line up against the widely followed narratives around Asker Healthcare Group’s growth, risks, and earnings quality.

Curious how numbers become stories that shape markets? Explore Community Narratives

EPS Trend Signals Stronger Profitability

• Basic EPS has moved from SEK0.19 in Q1 2025 to SEK0.57 in Q2 2026, while trailing twelve month EPS is SEK1.92, pointing to a much higher earnings base than a year ago where trailing EPS was SEK1.19.
• Bulls often point to this kind of earnings progress as a sign of a solid business, yet the latest 58.7% earnings growth and 9.8% 5 year annualized earnings growth both sit alongside a trailing net profit margin of 3.8% that is still relatively modest. Investors who are optimistic need to weigh the higher EPS against the fact that profitability is being earned on fairly tight margins.
  • The bullish angle that earnings growth could continue is supported by the 18% annual earnings growth forecast and the 7% annual revenue growth forecast, although forecasts are not guaranteed outcomes.
  • What stands out for a bullish view on Asker Healthcare Group is that revenue over the last six reported quarters has stayed in a relatively narrow range between SEK3,987m and SEK4,686m, yet net income moved from SEK60m in Q1 2025 to SEK219m in Q2 2026. This suggests the recent earnings power is being generated without relying on very rapid top line expansion.

Valuation Premium Versus Cash Flow And Targets

• At a share price of SEK77.85, Asker Healthcare Group trades above a DCF fair value estimate of SEK66.59 and on a P/E of 43.6x compared with industry and peer averages of 20.5x and 30.1x. Analysts’ price target of SEK97.00 implies roughly 24.6% upside from the current price.
• Critics highlight that such a valuation premium builds in a lot of optimism, and the data gives them some support because the stock price is already above the DCF fair value and materially above sector P/E levels. Even though analysts see room between SEK77.85 and their SEK97.00 target, anyone worried about overpaying has to decide how much weight to put on those higher earnings and revenue forecasts.
  • The bearish angle that investors might be paying too much is anchored in the 43.6x P/E against a sector on 20.5x and peers on 30.1x, which shows that Asker Healthcare Group carries a clear premium based on trailing earnings.
  • At the same time, the upside implied by the SEK97.00 analyst target leans on forecasts of about 18% annual earnings growth and 7% annual revenue growth. The tension for a cautious investor is between the premium paid today and the expectation that those growth rates will eventually justify it.

Margins And Debt Shape The Risk Profile

• Trailing net profit margin sits at 3.8% compared with 2.7% a year earlier, and this improvement comes with a high level of debt on the balance sheet, which is flagged as a key risk alongside the company’s growth profile.
• Bears argue that high leverage can limit flexibility, and here the numbers give that concern some context because the margin is still in the low single digits even after moving from 2.7% to 3.8%. A heavily debt funded structure leaves less room if profitability comes under pressure or if earnings grow more slowly than the recent 58.7% one year gain.
  • The combination of a 3.8% net margin and high debt means a larger share of cash flows may need to be reserved for servicing obligations, which can matter when the share already trades above the SEK66.59 DCF fair value.
  • For investors watching risk closely, the contrast between strong recent EPS figures and a balance sheet described as highly leveraged is central to judging how resilient Asker Healthcare Group’s current profitability really is.

📊 Read the what the Community is saying about Asker Healthcare Group.

Next Steps

Don't just look at this quarter; the real story is in the long-term trend. We've done an in-depth analysis on Asker Healthcare Group's growth and its valuation to see if today's price is a bargain. Add the company to your watchlist or portfolio now so you don't miss the next big move.

Seeing both risks and rewards in Asker Healthcare Group’s latest numbers and the valuation debate? Act now by reviewing the data directly and weighing the 3 key rewards and 1 important warning sign.

See What Else Is Out There

Asker Healthcare Group combines a relatively modest 3.8% net margin with high debt and a share price that already sits above a DCF fair value estimate.

If that mix of tight profitability, leverage, and a premium P/E concerns you, compare it with companies in the 293 resilient stocks with low risk scores to find stocks with more resilient risk profiles.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com